Rems | Jotup

Top 10 Best Practices for Website Accessibility Design and Development from a Leading Design Agency in the SF Bay Area

Retrieved on:

onsdag, april 10, 2024

BERKELEY, Calif., April 10, 2024 /PRNewswire-PRWeb/ -- Have you ever turned on the speech reader on your Mac and closed your eyes while navigating a website? It's a powerful test to learn how visually impaired people might experience your content.

Key Points:

With the evolving landscape of digital content, it's essential for us as designers to stay up-to-date with the latest accessibility standards and best practices.
Many of these guidelines are considered best practices in website design and development; a few, however, are easy to overlook.
Alt text is an essential part of website accessibility, as it describes the content of images to visually impaired users.
Some of us from P6 enjoyed the Smashing SF Conference which had several sessions on accessibility, front-end design, boosting web performance, and more.

Caeleb Dressel Dives into Nulo's 'Fuel Incredible' Campaign with Jane and Rems

Retrieved on:

tisdag, april 9, 2024

Veterinary, Sports, Pets, Fitness & Nutrition, Swimming, Food, Beverage, Health, Consumer, Retail, Partnership, Rems, Athlete, Pet, Multimedia, Family, Motivation, Happiness, Water

In an inspiring new chapter for pet and athlete partnerships, Nulo is proud to announce its collaboration with swimming legend Caeleb Dressel and his pets, Jane the English Labrador and Rems the cat, for its "Fuel Incredible" campaign.

Key Points:

In an inspiring new chapter for pet and athlete partnerships, Nulo is proud to announce its collaboration with swimming legend Caeleb Dressel and his pets, Jane the English Labrador and Rems the cat, for its "Fuel Incredible" campaign.
This initiative spotlights the invaluable role pets play in supporting the mental and physical health of world-class athletes.
View the full release here: https://www.businesswire.com/news/home/20240409049026/en/
7-time gold medalist Caeleb Dressel credits part of his success and his record-breaking speed to the support system he finds in his dog Jane and cat Rems.
Reflecting on the partnership, Dressel shared, “Jane and Rems are more than just pets; they’re my family and my biggest supporters.

Zogenix Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on:

torsdag, augusti 5, 2021

Research and development expenses for the second quarter endedJune 30, 2021, totaled$36.6 million, up from$34.4 millionin the second quarter endedJune 30, 2020, as spending for FINTEPLA across all indications remained relatively flat, and the Company incurred increased costs in its MT1621 program.

Key Points:

Research and development expenses for the second quarter endedJune 30, 2021, totaled$36.6 million, up from$34.4 millionin the second quarter endedJune 30, 2020, as spending for FINTEPLA across all indications remained relatively flat, and the Company incurred increased costs in its MT1621 program.
Net loss for the second quarter endedJune 30, 2021, was$58.9 million, or a net loss of$1.05per share, compared with a net loss of$53.3 million, or a net loss of$0.96per share, in the second quarter endedJune 30, 2020.
Six Months EndedJune 30, 2021Financial Results Compared to Six Months EndedJune 30, 2020
The Company recorded$32.5 millionin revenue for the six months endedJune 30, 2021.
As ofJune 30, 2021, the Company had$393.0 millionin cash, cash equivalents, and marketable securities, compared to$505.1 millionatDecember 31, 2020.

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Retrieved on:

lördag, juni 26, 2021

Opioids, Drugs, Psychoactive drugs, Euphoriants, Camurus, Lund, Substance dependence, Opioid use disorder, Drug rehabilitation, Risk Evaluation and Mitigation Strategies, Buprenorphine, Rems

If approved, Brixadi would be used as part of a complete treatment plan to include counseling and psychosocial support.

Key Points:

If approved, Brixadi would be used as part of a complete treatment plan to include counseling and psychosocial support.
Brixadi will be available through a Risk Evaluation and Mitigation Strategy (REMS) program and administered only by healthcare providers in a healthcare setting.
Brixadi is the US trademark for Camurus' product Buvidalapproved for treatment of opioid dependence in the EU, UK, Australia, Switzerland and New Zealand.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Camurus announces PDUFA date for Brixadi for the treatment of opioid use disorder in the US

Retrieved on:

lördag, juni 26, 2021

Opioids, Drugs, Psychoactive drugs, Euphoriants, Camurus, Lund, Substance dependence, Opioid use disorder, Drug rehabilitation, Risk Evaluation and Mitigation Strategies, Buprenorphine, Rems

If approved, Brixadi would be used as part of a complete treatment plan to include counseling and psychosocial support.

Key Points:

If approved, Brixadi would be used as part of a complete treatment plan to include counseling and psychosocial support.
Brixadi will be available through a Risk Evaluation and Mitigation Strategy (REMS) program and administered only by healthcare providers in a healthcare setting.
Brixadi is the US trademark for Camurus' product Buvidalapproved for treatment of opioid dependence in the EU, UK, Australia, Switzerland and New Zealand.
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine

Retrieved on:

måndag, mars 29, 2021

For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.

Key Points:

For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
Adempas, the first sGC stimulator of this collaboration, is developed by Bayer and MSD.
For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
Our online press service is just a click away: www.bayer.us/en/newsroom
BAYER, the Bayer Cross, and Adempas(R) are registered trademarks of Bayer.

High Sierra Electronics Announces Innovative New Remote Erosion Monitoring System for Levees

Retrieved on:

tisdag, februari 23, 2021

Physical geography, Flood control, Levee, Riparian zone, Rems, Flood, Telemetry, Earth sciences, Nature

The system, known as REMS, short for Remote Erosion Monitoring System, uses a series of beacon sensors that are embedded at levee sites that are prone to erosion.

Key Points:

The system, known as REMS, short for Remote Erosion Monitoring System, uses a series of beacon sensors that are embedded at levee sites that are prone to erosion.
"At High Sierra Electronics, our expertise for the past 29 years is real-time monitoring using sensors and telemetry.
Click here to learn more about REMS, Remote Erosion Monitoring System for levees.
High Sierra Electronics' systems help identify threats posed by the weather, which include flooding, dangerous road conditions, and vulnerable dams and levees.

Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting

Retrieved on:

onsdag, maj 13, 2020

Oncology, Health, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Cancer treatments, Medicine, Health, Clinical medicine, Axicabtagene ciloleucel, Breakthrough therapy, Gene therapy, Risk Evaluation and Mitigation Strategies, Rems, Gilead, The Handmaid's Tale

Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution.

Key Points:

Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving Yescarta, including concurrently with CRS or after CRS resolution.
Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS.
All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.
Learn more about Gilead at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Coronavirus (COVID-19) Update: FDA provides update on patient access to certain REMS drugs during COVID-19 public health emergency

Retrieved on:

söndag, mars 22, 2020

Health, Food and Drug Administration, Articles, Rems, Risk Evaluation and Mitigation Strategies

We will continue to work with sponsors to ensure that patients have appropriate access to the medications they need."

Key Points:

We will continue to work with sponsors to ensure that patients have appropriate access to the medications they need."
The FDA does not intend to take action against sponsors and others for the duration of the public health emergency for failing to adhere to REMS requirements for certain laboratory testing or imaging studies.
The FDA also may require certain elements to assure safe use (ETASU) as part of REMS for a drug.
The policy outlined in the guidance will be in effect for the duration of the public health emergency.

Kite Announces New Yescarta® Data From ZUMA-1

Retrieved on:

måndag, juni 3, 2019

Health, Biotechnology, Clinical trials, Hospitals, Oncology, Pharmaceutical, Health, Articles, Cancer treatments, Gene therapy, Drug Safety, Food and Drug Administration, Risk Evaluation and Mitigation Strategies, Rems, Axicabtagene ciloleucel, Pharmacovigilance

Kite is currently conducting various studies to further evaluate the efficacy and safety profile of Yescarta, including clinical trials evaluating use of bridging chemotherapy and other combination approaches.

Key Points:

Kite is currently conducting various studies to further evaluate the efficacy and safety profile of Yescarta, including clinical trials evaluating use of bridging chemotherapy and other combination approaches.
Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS.
YESCARTA REMS: Because of the risk of CRS and neurologic toxicities, Yescarta is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Yescarta REMS.
All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation to update any such forward-looking statements.